Cancer Crusaders Inc
Metairie, Louisiana
B+Health Score
71B+
Financial Health Score
8-metric score across financial health, operational efficiency, and resilience. Based on IRS Form 990 filing data.
Good
💰
$638K
Total Revenue
📊
$240K
Total Expenses
🏦
$626K
Net Assets
📋
N/A
Total Liabilities
Financial Trends
5-Year Trend Analysis
Financial Health Indicators
Revenue Growth
+171.2%
Year-over-year change (2022 → 2023)
Net Margin
+62.3%
Revenue minus expenses as % of revenue
Filing History
13 filings on record| Year | Revenue | Expenses | Assets | |
|---|---|---|---|---|
| 2023 | $637,866↑171% | $240,484↑49% | $625,956↑191% | — |
| 2022 | $235,200↑56% | $161,664↑77% | $214,872↑45% | — |
| 2021 | $151,209↑71% | $91,109↓34% | $148,336↑68% | — |
| 2020 | $88,491↓38% | $138,748↓24% | $88,236↓36% | — |
| 2019 | $142,496↓22% | $182,524↑1% | $138,493↓22% | — |
| 2018 | $182,565 | $180,145↓19% | $178,521↑1% | — |
| 2017 | $181,777↓18% | $222,822↓6% | $176,101↓19% | — |
| 2016 | $220,961↓8% | $237,161↑1% | $217,146↓7% | — |
| 2015 | $239,530↑1% | $234,004↓15% | $233,346↑2% | — |
| 2014 | $236,680↓13% | $273,943↑27% | $227,820↓14% | — |
| 2013 | $272,173↑27% | $215,078↑3% | $265,083↑27% | — |
| 2012 | $214,560↑3% | $209,000↓9% | $207,988↑3% | — |
| 2011 | $207,583 | $229,526 | $202,428 | — |
Frequently Asked Questions
What does Cancer Crusaders Inc do?▼
Cancer Crusaders Inc is a diseases, disorders & medical disciplines nonprofit organization based in Louisiana. It is classified under NTEE code G30Z and is registered as a 501(c) tax-exempt organization with the IRS.
Is Cancer Crusaders Inc financially healthy?▼
Financial health scoring requires Form 990 filing data. Check back as we process more filings for Cancer Crusaders Inc.
How much revenue does Cancer Crusaders Inc generate?▼
Cancer Crusaders Inc reports $238K in annual revenue and holds $592K in total assets, based on IRS filings.
Similar Organizations
Explore more organizations in the Diseases, Disorders & Medical Disciplines category, or browse all nonprofits in Louisiana.